methyl {4,6-diamino-2-[3-(2,6-difluoro-3-methylbenzyl)-5-fluoro-1H-indazol-1-yl]pyrimidin-5-yl}carbamate | 1337566-68-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: methyl {4,6-diamino-2-[3-(2,6-difluoro-3-methylbenzyl)-5-fluoro-1H-indazol-1-yl]pyrimidin-5-yl}carbamate
• 英文别名: methyl N-[4,6-diamino-2-[3-[(2,6-difluoro-3-methylphenyl)methyl]-5-fluoroindazol-1-yl]pyrimidin-5-yl]carbamate
• CAS: 1337566-68-3
• 化学式: C₂₁H₁₈F₃N₇O₂
• 分子量: 457.415
• InChiKey: BVZOPNMHMWDRKT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  33
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  134
• 氢给体数：
  3
• 氢受体数：
  10

文献信息

• SOLUBLE GUANYLATE CYCLASE ACTIVATORS
  申请人：Schmidt Darby

  公开号：US20130012511A1

  公开（公告）日：2013-01-10

  The invention relates to compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, which are soluble guanylate cyclase activators. The compounds are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.
• US9284301B2
  申请人：——

  公开号：US9284301B2

  公开（公告）日：2016-03-15